The Surge in Global Biotech Innovation

• Biotech capital markets in 2020 raised $55 billion in equity financing, significantly surpassing the $28 billion raised in both 2018 and 2019.
• Market expansion is driven by supply-side advancements in genomic medicine, precision oncology, and gene therapy, alongside investor demand for external innovation.
• Large-cap pharmaceutical companies are actively seeking collaborations and acquisitions to access novel therapeutic technologies.
• COVID-19-related stocks have collectively added over $50 billion in market capitalization this year.
• Pfizer, BioNTech, Moderna, Eli Lilly, and Regeneron have deployed significant capital and cutting-edge technology toward vaccine and therapeutic development.
• Pfizer and BioNTech reported 95% efficacy in Phase 3 data for their vaccine candidate, with consistency across age, gender, and ethnicity.
• The Pfizer/BioNTech vaccine is projected to likely support emergency use authorization and potential full approval by December 2020 or January 2021.
• Moderna's vaccine candidate demonstrated similar efficacy with slightly improved storage requirements.
• Goldman Sachs anticipates a multi-player success model in the vaccine market due to the breadth and depth of the pandemic.
• Total biopharma M&A activity for 2020 was approximately $50 billion, a decrease from $140 billion in 2018 and $220 billion in 2019.
• M&A activity experienced a pronounced pause during the initial pandemic phase but accelerated dramatically in late summer 2020.
• Robust M&A activity is forecasted for Q4 2020 and throughout 2021, supported by pipeline gaps and loss-of-exclusivity events (patent cliffs) for large-cap pharma.
• Large-cap pharmaceuticalers possess significant "dry powder" capital, further incentivized by reduced tax reform risk under a divided U.S. government.
• CEO confidence in business visibility post-COVID is identified as a primary driver for capitalizing on M&A opportunities in 2021.

Geopolitical and China-Specific Trends

• Cross-border biotech innovation between the U.S./Europe and China has shifted from a manufacturing/commercialization focus to deep R&D collaboration.
• U.S. and European multinationals are now out-licensing innovative assets to Chinese biotechs for development and inclusion in global approval data.
• Novel oncology assets are increasingly being licensed from Chinese companies into U.S. and European markets.
• Multiple multi-billion dollar deals have recently been announced involving U.S., European, and Chinese entities.
• The "sea turtle" phenomenon—PhDs trained in the U.S. and Europe returning to China—has seeded a wave of innovation.
• Chinese government initiatives, including "Made in China 2025" and the next five-year plan, prioritize domestic biotech ecosystem building.
• 60 healthcare companies listed in China and Hong Kong this year, raising $16 billion in Hong Kong alone.
• Goldman Sachs projects that Chinese biotechs will transition from domestic leaders to global competitors over the coming decade.